Navigation Links
PCAS : Tighter Links Between PCAS and Proteus
Date:10/22/2007

LONGJUMEAU, France, October 22 /PRNewswire-FirstCall/ -- Proteus today announced the completion of a share capital increase reserved for Proteus' industrial partner PCAS. PCAS' stake in Proteus now represents 32% of the issued share capital vs 6% before the increase. Proceeds of this private placement are to be used to accelerate the growth of PROTEUS' PSI and PCAS BIOSOLUTION businesses.

PROTEUS (http://www.proteus.fr) is a biotech company discovering, optimizing, developing and producing new proteins and biotechnological processes for pharmaceuticals, cosmetics, fine chemicals, environmental and other industrial applications. PROTEUS' business is backed by a unique set of technologies, know how and intellectual property portfolio including exclusive resources in natural microbial biodiversity and proprietary technologies for screening, engineering and producing proteins.

PROTEUS offers a range of exclusive solutions for protein manufacturing and engineering through a dedicated business unit "PSI" (Proteus Services for Industry) and through exclusive industrial partnerships. The new proteins and process developed by PROTEUS reinforce the competitive edge and intellectual property position of its clients.

PCAS and PROTEUS already entered into close partnership by forming PCAS BIOSOLUTION, a 50/50 joint venture. The mission of PCAS BIOSOLUTION (http://www.pcas-bio.com) is to design, develop and industrialize new manufacturing routes to produce pharmaceutical intermediates and actives compounds ("API"). The new routes combines chemical processes developed by PCAS and enzymatic catalytic processes ("biocatalysis") developed by PROTEUS.

PCAS thus reinforces its position in "green chemistry", providing its clients with all the benefits of integrating chemistry and biotechnology. The new chemo-biocatalytic processes developed at PCAS BIOSOLUTION enable to access to complex pharmaceutical intermediates while reducing the number of steps of the manufacturing process, lowering the production costs and reducing the amount of waste. With PCAS BIOSOLUTION, PROTEUS improves and widens its offering to the life science industry by providing industrial manufacturing services backed by the expertise and industrial capabilities of PCAS, a leading European player in the field.

PCAS (http://www.pcas.fr) is a group listed on the Eurolist compartment C (ISIN FR0000053514), specialized in fine and specialty chemicals. It develops and manufactures high added-value molecules or molecules of a strong technological content for the pharmaceutical, perfume, cosmetic and industrial sectors.

Contact :

GĂ©rard Guillamot,

+33(0)1-69-79-60-08

http://www.pcas.fr


'/>"/>
SOURCE PCAS
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Investor links East Coast funds to Midwest tech
2. UW links with Israeli school to locate genes
3. New Dane County airport links to Atlanta announced
4. Big collaboration links learners to science on a tiny scale
5. ARI Links e-Catalog Deal with Outdoor Power Equipment Manufacturer
6. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
7. Quantitative Measurement of Cell Proliferation Using the BrdU ELISA: A Comparison Between Colorimetric and Chemiluminescent Detection
8. Monitoring fluorescence resonance energy transfer (FRET) between GFP fusions in lysates of the yeast Saccharomyces cerevisiae using the Varian Cary Eclipse
9. Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP
10. Single gene controls key difference between maize and its wild ancestor
11. Line between big pharma, big biotech continues to blur
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017  United ... announced its financial results for the fourth quarter ... annual 2016 financial results reflect continued growth as ... $700 million," said Martine Rothblatt, Ph.D., United Therapeutics, ... strengthen our ability to develop and advance our ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Biopsy System , a fully automated benchtop system for collecting intact circulating tumor ... being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... -Sciences division, Treximo will pair its $200M operational capacity with its strategic ... project management in areas affecting quality and operational management. With office ...
(Date:2/21/2017)... Feb. 21, 2017  Lexus, a returning partner of the ... official and exclusive automobile partner of the men,s and women,s events ... The 2017 Amgen Tour of California ... some of the best professional cycling teams in the world racing ... The four-day Amgen Breakaway from Heart Disease TM ...
Breaking Biology Technology:
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):